Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $491,484.70 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 10,235 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $48.02, for a total transaction of $491,484.70. Following the completion of the transaction, the chief executive officer owned 1,144,336 shares in the company, valued at approximately $54,951,014.72. This represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $47.96 on Friday. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $48.64. The company has a market cap of $2.69 billion, a P/E ratio of 41.70 and a beta of 0.78. The firm’s fifty day moving average price is $43.23 and its two-hundred day moving average price is $36.00.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SUPN. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Piper Sandler boosted their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research report on Friday, August 29th. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $51.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Two Sigma Advisers LP raised its stake in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company’s stock valued at $282,000 after purchasing an additional 1,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Supernus Pharmaceuticals by 24.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 100,020 shares of the specialty pharmaceutical company’s stock valued at $3,617,000 after purchasing an additional 19,824 shares in the last quarter. Versant Capital Management Inc raised its stake in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares in the last quarter. GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals by 4,005.4% in the first quarter. GAMMA Investing LLC now owns 43,230 shares of the specialty pharmaceutical company’s stock valued at $1,320,000 after purchasing an additional 42,177 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Supernus Pharmaceuticals by 17.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 77,610 shares of the specialty pharmaceutical company’s stock valued at $2,542,000 after purchasing an additional 11,304 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.